Noriyasu Kamei

Dr. Noriyasu Kamei

Laboratory of Drug Delivery Systems, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Advanced Science
Verified
Journal Article
Open access
AZAntje Zickler
Antje Zickler
XLXiuming Liang
Xiuming Liang
DGDhanu Gupta
Dhanu Gupta
DMDoste R. Mamand
Doste R. Mamand
MLMariacristina De Luca
Mariacristina De Luca
OGOskar Gustafsson
Oskar Gustafsson
Messenger RNA (mRNA) has emerged as an attractive therapeutic molecule for a plethora of clinical applications. For in vivo functionality, mRNA therapeutics require encapsulation into effective, stable, and safe delivery systems to protect the cargo from degradation and reduce immunogenicity. Here, a bioengineering platform for efficient mRNA loading and functional delivery using bionormal nanoparticles, extracellular vesicles (EVs), is established by expressing a highly specific RNA‐binding domain fused to CD63 in EV producer cells stably expressing the target mRNA. The additional combination with a fusogenic endosomal escape moiety, Vesicular Stomatitis Virus Glycoprotein, enables functional mRNA delivery in vivo at doses substantially lower than currently used clinically with synthetic lipid‐based nanoparticles. Importantly, the application of EVs loaded with effective cancer immunotherapy proves highly effective in an aggressive melanoma mouse model. This technology addresses substantial drawbacks currently associated with EV‐based nucleic acid delivery systems and is a leap forward to clinical EV applications.

5 December 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NKNoriyasu Kamei
Noriyasu Kamei
NONobuyuki Okada
Nobuyuki Okada
TITakamasa Ikeda
Takamasa Ikeda
HCHayoung Choi
Hayoung Choi
YFYui Fujiwara
Yui Fujiwara
MTMariko Takeda-Morishita
Mariko Takeda-Morishita
In a recent study, we demonstrated the potential of a cell-penetrating peptide (CPP) penetratin to deliver the peptide drug insulin to the brain via nasal administration, and its pharmacological effect on the mild cognitive dysfunction in senescence-accelerated mouse (SAMP8). However, the therapeutic potential of intranasal insulin administration was attenuated when applied to the aged SAMP8 with severe cognitive dysfunction. The present study, therefore, aimed to overcome the difficulty in treating severe cognitive dysfunction using insulin by investigating potential alternatives, glucagon-like peptide-1 (GLP-1) receptor agonists such as exendin-4. Examination using normal ddY mice demonstrated that the distribution of exendin-4 throughout the brain was dramatically increased by intranasal coadministration with the L-form of penetratin. The activation of hippocampal insulin signaling after the simultaneous nose-to-brain delivery of exendin-4 and an adequate level of insulin were confirmed by analyzing the phosphorylation of Akt. Furthermore, spatial learning ability, evaluated in the Morris water maze test after daily administration of exendin-4 with L-penetratin and supplemental insulin for 4 weeks, suggested therapeutic efficacy against severe cognitive dysfunction. The present study suggests that nose-to-brain delivery of exendin-4 with supplemental insulin, mediated by CPP coadministration, shows promise for the treatment of progressive cognitive dysfunction in SAMP8.

1 March 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
EKEl-Sayed Khafagy
El-Sayed Khafagy
NKNoriyasu Kamei
Noriyasu Kamei
YFYui Fujiwara
Yui Fujiwara
HOHaruka Okumura
Haruka Okumura
TYTeruyo Yuasa
Teruyo Yuasa
MTMariko Takeda-Morishita
Mariko Takeda-Morishita

20 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NKNoriyasu Kamei
Noriyasu Kamei
SSSusumu Suwabe
Susumu Suwabe
KAKenji Arime
Kenji Arime
HBHidemi Bando
Hidemi Bando
KMKaho Murata
Kaho Murata
MTMariko Takeda-Morishita
Mariko Takeda-Morishita
We previously found that coadministering peptides and proteins with the cell-penetrating peptide L-penetratin intranasally significantly increased transport to the brain and enhanced pharmacological effects. The present study aimed to clarify the mechanisms of nose-to-brain drug delivery enhancement by L-penetratin coadministration. First, we compared the concentrations of Exendin-4 in plasma and brain after intranasal and subcutaneous administration and suggested that coadministration with L-penetratin facilitated the direct nose-to-brain transport of Exendin-4. Second, we demonstrated that L-penetratin did not stimulate the transport of Cy7-labeled Exendin-4 and insulin through the trigeminal nerves but shifted their distribution to the olfactory mucosal pathway. Third, we investigated the distribution of insulin into the deeper regions of the brain after delivery via the olfactory pathway and suggested that insulin had entered the olfactory bulb, bottom part of the brain, and perivascular space through the cerebrospinal fluid and had diffused throughout the brain. We further demonstrated that intranasally delivered insulin with L-penetratin specifically accumulated on the hippocampus neuronal cells. Thus, this study suggested that administrating peptide drugs intranasally with L-penetratin allows direct transport to the olfactory bulb, bottom part of the brain, and perivascular space of the cerebral artery. This technique also potentially allows targeting of specific brain areas.

9 January 2023 in The FASEB Journal
Verified
Journal Article
Open access
MIMai Itagaki
Mai Itagaki
YNYoshinori Nasu
Yoshinori Nasu
CSChiaki Sugiyama
Chiaki Sugiyama
INIkuhiko Nakase
Ikuhiko Nakase
NKNoriyasu Kamei
Noriyasu Kamei
Endocytosis is an essential biological process for nutrient absorption and intercellular communication; it can also be used to accelerate the cellular internalization of drug delivery carriers. Clarifying the cellular uptake mechanisms of unidentified endogenous and exogenous molecules and designing new effective drug delivery systems require an accurate, specific endocytosis analysis methodology. Therefore, we developed a method to specifically evaluate cellular internalization via three main endocytic pathways: clathrin‐ and caveolae‐mediated endocytosis, and macropinocytosis. We first revealed that most known endocytosis inhibitors had no specific inhibitory effect or were cytotoxic. Second, we successfully established an alternative method using small interfering RNA to knock down dynamin‐2 and caveolin‐1, which are necessary for clathrin‐ and caveolae‐mediated endocytosis, in HeLa cells. Third, we established another method to specifically analyze macropinocytosis using rottlerin on A431 cells. Finally, we validated the proposed methods by testing the cellular internalization of a biological molecule (insulin) and carriers (nanoparticles and cell‐penetrating peptides). Through this study, we established versatile methods to precisely and specifically evaluate endocytosis of newly developed biopharmaceuticals or drug delivery systems.

1 July 2021 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
NKNoriyasu Kamei
Noriyasu Kamei
HNHaruka Nishimura
Haruka Nishimura
AMAtsushi Matsumoto
Atsushi Matsumoto
RARiho Asano
Riho Asano
KMKanae Muranaka
Kanae Muranaka
MTMariko Takeda-Morishita
Mariko Takeda-Morishita